Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole Propanoic Acid
2. Bay U 3405
3. Bay U 3406
4. Bay U-3405
5. Bay U3405
1. 116649-85-5
2. Baynas
3. Bay U3405
4. Bay U 3405
5. Bay-u-3405
6. Bay-u 3405
7. 3-[(3r)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic Acid
8. (+)-(3r)-3-(p-fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic Acid
9. P1ali72u6c
10. (r)-3-(3-(4-fluorophenylsulfonamido)-3,4-dihydro-1h-carbazol-9(2h)-yl)propanoic Acid
11. 9h-carbazole-9-propanoic Acid, 3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-, (3r)-
12. En-137774
13. Chembl361812
14. Ncgc00167519-01
15. En 137774
16. Bay U 3406
17. Bay U-3405
18. (3r)-3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic Acid
19. Dsstox_cid_26685
20. Dsstox_rid_81819
21. Dsstox_gsid_46685
22. [3h]ramatroban
23. [3h]baynas
24. Baynas (tn)
25. Cas-116649-85-5
26. Ramatroban (jan/inn)
27. Ramatroban [inn:ban]
28. Unii-p1ali72u6c
29. 3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole Propanoic Acid
30. [3h]bay U 3405
31. [3h]bay U3405
32. 3r-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic Acid
33. (3r)-3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic Acid
34. 9h-carbazole-9-propanoic Acid, 3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-, (3r)-
35. Mfcd00887606
36. Ramatroban [mi]
37. Ramatroban [inn]
38. Ramatroban [jan]
39. Ramatroban [mart.]
40. 9h-carbazole-9-propanoic Acid, 3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-, (r)-
41. Ramatroban [who-dd]
42. Ramatroban (bay U3405)
43. Schembl29030
44. Mls006010637
45. Gtpl1910
46. Gtpl1911
47. Dtxsid1046685
48. Chebi:32087
49. Hms3648e21
50. Bay U3405;bay-u3405
51. Ex-a4208
52. Hy-b0745
53. Zinc3798772
54. Tox21_112516
55. Ac-719
56. Bdbm50161746
57. S5286
58. Akos015966619
59. Ramatroban, >=98% (hplc), Solid
60. Tox21_112516_1
61. Ccg-268842
62. Db13036
63. Ks-1310
64. Ncgc00167519-02
65. Ncgc00167519-04
66. Ncgc00167519-07
67. Smr002530322
68. R0144
69. D01128
70. 649f855
71. A803658
72. Sr-01000883932
73. Sr-01000946208
74. J-003466
75. Sr-01000883932-1
76. Sr-01000946208-1
77. Q10357327
78. (r)-3-(3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydrocarbazol-9-yl)propanoic Acid
79. (r)-3-(3-(4-fluorophenylsulfonamido)-3,4-dihydro-1h-carbazol-9(2h)-yl)propanoicacid
80. [(4-fluorophenyl)sulfonylamino] 3-(1,2,3,4-tetrahydrocarbazol-9-yl)propanoate
81. 3(r)-[[(4-fluoro-phenyl) Sulfonyl]amino]-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic Acid
82. 3-[(r)-3-(4-fluoro-benzenesulfonylamino)-1,2,3,4-tetrahydro-carbazol-9-yl]-propionic Acid
83. A8x
Molecular Weight | 416.5 g/mol |
---|---|
Molecular Formula | C21H21FN2O4S |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 416.12060649 g/mol |
Monoisotopic Mass | 416.12060649 g/mol |
Topological Polar Surface Area | 96.8 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 689 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
ABOUT THIS PAGE
A Ramatroban manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ramatroban, including repackagers and relabelers. The FDA regulates Ramatroban manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ramatroban API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ramatroban manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ramatroban supplier is an individual or a company that provides Ramatroban active pharmaceutical ingredient (API) or Ramatroban finished formulations upon request. The Ramatroban suppliers may include Ramatroban API manufacturers, exporters, distributors and traders.
click here to find a list of Ramatroban suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Ramatroban Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ramatroban GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ramatroban GMP manufacturer or Ramatroban GMP API supplier for your needs.
A Ramatroban CoA (Certificate of Analysis) is a formal document that attests to Ramatroban's compliance with Ramatroban specifications and serves as a tool for batch-level quality control.
Ramatroban CoA mostly includes findings from lab analyses of a specific batch. For each Ramatroban CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ramatroban may be tested according to a variety of international standards, such as European Pharmacopoeia (Ramatroban EP), Ramatroban JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ramatroban USP).
LOOKING FOR A SUPPLIER?